- Phebra takes part ownership of Flexipharm Austrading through share purchase
- Builds on Phebra's Existing UK Distribution Agreement
- Strengthens Phebra’s Presence in UK and Europe

Sydney, Australia and Bourne End, UK,  02 November, 2021:  Leading Australian 
pharmaceutical group Phebra Holdings ('Phebra') is pleased to announce that it 
has completed a share purchase agreement with the UK hospital specialty 
pharmaceutical company Flexipharm Austrading Limited ('FAL'). 

Flexipharm Austrading, a privately-owned company founded in 2018 by experienced 
specialty pharma expert, Michael Clark, focuses on supplying UK hospitals with 
Better Critical Care Medicines. Flexipharm Austrading has an existing licence 
and distribution agreement with Phebra for the supply of products from Phebra's 
portfolio of critical care medicines; to date several products have been 
approved and successfully launched in the UK.

Andre Vlok, Chief Executive Officer Phebra, said: 'We are excited that Phebra 
has made this strategic investment in Flexipharm Austrading. This is a logical 
next step for Phebra, deepening a strong and successful collaboration built 
over the last 3 years. It strengthen Phebra's access to the key UK market which 
is very important for our current and future pipeline of critical care 
products." 

"Our partnership will allow us to leverage the existing infrastructure at FAL 
under the expert leadership of Michael and to advance our route to market in 
the UK and potentially, expand our international sales into wider, selected 
European markets."

Michael Clark, Founder and Managing Director of Flexipharm Austrading, said: "I 
established the business with a goal to supply UK hospitals with Better 
Critical Care Medicines; Phebra had a portfolio of products that we believed 
offered advantages over existing products and together we have successfully 
launched these in the UK. But the job is only part-completed; I am delighted 
that Phebra is now a shareholder and look forward to deepening this 
relationship which is based around supplying hospitals with a focus on improved 
or novel versions of gold standard drugs and offering tangible and transparent 
value to the NHS, healthcare professionals and, independent hospitals." 

About Phebra
Phebra is an Australian based specialty pharmaceutical group which develops, 
manufactures and markets critical medicines across the world. 

At Phebra, we create critical medicines that save and improve lives.

About Flexipharm Austrading
Flexipharm Austrading's vision is to become a UK-based specialty pharmaceutical 
company that is genuinely respected and trusted by NHS hospitals. It was 
founded in 2018 by Michael Clark, an experienced specialty pharmaceutical 
company founder and board director. Flexipharm Austrading has a singular focus 
on commercialising established molecules embedded in hospital use where there 
are concerns around security of ongoing supply; where the current presentation 
is not optimal for the needs of the NHS staff; and where the current 
presentations can contribute to medication errors. The Company has a deep 
understanding of the conditions where its medicines are used and builds 
enduring meaningful dialogue with the NHS staff involved in using these 
medicines. It works in partnership with Phebra Pty Ltd, an Australian 
pharmaceutical company developing and manufacturing injectable pharmaceutical 
products. For further information visit www.flexipharmaustrading.com.

SOURCE: Phebra